|
|||||
|
|
Immune checkpoint inhibitor‐related cutaneous adverse events |
|
| Authors: | Chunxia He Tao Qu |
| Abstract: | Cutaneous toxicities are the most prevalent immune‐related adverse events. Various reactions have been reported. In this review, we summarized the clinicopathologic manifestations, treatment strategies, relevance to tumor outcomes, and rechallenge considerations of cutaneous immune‐related adverse events. |
| Keywords: | cutaneous toxicities immune checkpoint inhibitors immune‐related adverse events outcomes rechallenge |